Literature DB >> 8616875

Phorbol ester and cyclic AMP-mediated regulation of the melanoma-associated cell adhesion molecule MUC18/MCAM.

M M Rummel1, C Sers, J P Johnson.   

Abstract

MUC18/MCAM is a melanoma-associated cell adhesion molecule that is also occasionally found on carcinomas and other tumor types. On melanomas, MUC18 expression increases with tumor progression and is found on more than 70% of metastatic lesions. To investigate the regulation of MUC18 expression, cell lines of diverse tissue origin were exposed to cytokines, regulators of intracellular cyclic AMP (cAMP), and to phorbol ester. MUC18 expression could not be induced in negative cell lines and could only be modulated by changes in cAMP levels or by exposure to phorbol ester in positive cells. An increase in intracellular cAMP led to an up-regulation in cell surface MUC18 that was maximal at 48 h. Increased MUC18 mRNA levels were observed as soon as 4 h and were 3-fold higher than in control cells by 48 h. Exposure of the cells to phorbol ester reduced MUC18 surface expression to background levels by 24 h. This downregulation was associated with decreased mRNA levels that were apparent at 8 h. By 24 h, steady-state levels of MUC18 mRNA had been reduced by 58%. Whereas similar changes in MUC18 surface expression were observed in MUC18-expressing glioma and carcinoma cell lines, melanoma cells were more resistant to the MUC18-modulating effects of cAMP analogues and phorbol ester. These observations suggest that the strong MUC18 expression observed in advanced melanomas may reflect disturbances in the normal regulation of this molecule.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616875

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis.

Authors:  Vladislava O Melnikova; Krishnakumar Balasubramanian; Gabriel J Villares; Andrey S Dobroff; Maya Zigler; Hua Wang; Frederik Petersson; Janet E Price; Alan Schroit; Victor G Prieto; Mien-Chie Hung; Menashe Bar-Eli
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

Review 2.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

3.  Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146.

Authors:  Xuehui Chen; Huiwen Yan; Dan Liu; Qingji Xu; Hongxia Duan; Jing Feng; Xiyun Yan; Can Xie
Journal:  iScience       Date:  2021-04-14

Review 4.  Role of Biomarkers in the Integrated Management of Melanoma.

Authors:  Piyu Parth Naik
Journal:  Dis Markers       Date:  2021-12-30       Impact factor: 3.434

5.  CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer.

Authors:  Haofeng Zhang; Jun Zhang; Zhaoqing Wang; DI Lu; Jing Feng; Dongling Yang; Xiuqin Chen; Xiyun Yan
Journal:  Oncol Lett       Date:  2013-01-22       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.